Compare the three leading GLP-1 receptor agonist medications for Type 2 diabetes and weight loss: Ozempic (semaglutide), Mounjaro (tirzepatide), and Wegovy.

For each medication, research and provide:
1. The active ingredient and mechanism of action
2. FDA approval dates for diabetes and/or weight loss indications
3. Typical dosing schedule
4. Average weight loss percentage reported in clinical trials
5. Common side effects

Then provide:
6. A comparative analysis of efficacy and safety profiles
7. Current availability challenges or shortages if any

FORMAT YOUR RESPONSE AS:
```
## Ozempic (semaglutide)
- Mechanism: [description]
- FDA Approvals: [dates and indications]
- Dosing: [schedule]
- Weight Loss: [clinical trial results]
- Side Effects: [list]

## Mounjaro (tirzepatide)
- Mechanism: [description]
- FDA Approvals: [dates and indications]
- Dosing: [schedule]
- Weight Loss: [clinical trial results]
- Side Effects: [list]

## Wegovy
- Mechanism: [description]
- FDA Approvals: [dates and indications]
- Dosing: [schedule]
- Weight Loss: [clinical trial results]
- Side Effects: [list]

## Comparative Analysis
[2-3 sentences comparing efficacy and safety]

## Availability Status
[Current shortage or supply information]
```

All information must be grounded in web search results.
